HUTCHMED Ltd (HCM) Form 6-K — Jun 12, 2026
HUTCHMED presented positive Phase III data for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) at the EHA 2026 Congress. The ESLIM-02 study met its primary endpoint, showing a 66% durable response rate for sovleplenib versus 15% for placebo (p<0.0001) over 24 weeks. The drug demonstrated superior efficacy across multiple metrics, including a 70% overall response rate versus 22% for placebo, and significantly reduced the need for rescue therapy (16% vs 54%) and blood transfusions (11% vs 43%). Sovleplenib showed a favorable safety profile with no treatment-related deaths or discontinuations.
Key figures
- Dose
- 300 mg once daily
- Placebo arm count
- 46
- Treatment duration
- 24 weeks
- Grade 3 teae placebo
- 59%
- Sovleplenib arm count
- 44
- Patient count phase iii
- 90
- Grade 3 teae sovleplenib
- 43%
- Transfusion rate placebo
- 43%
- Rescue therapy use placebo
- 54%
- Transfusion rate sovleplenib
- 11%
- Durable response rate placebo
- 15%
- Overall response rate placebo
- 22%
- Rescue therapy use sovleplenib
- 16%
- Median time to response placebo
- 6.3 weeks
- Durable response rate sovleplenib
- 66%
- Overall response rate sovleplenib
- 70%
- Median time to response sovleplenib
- 3.1 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.